Related Experiment Videos
Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab
1Department of Clinical Neurosciences, University of Calgary, Calgary, AB, Canada. corytoth@shaw.ca
Background:
Neurosarcoidosis is often a devastating, refractory condition without definite pharmacotherapies beyond corticosteroids.
Aim:
To describe a case of steroid-refractory neurosarcoidosis with a marked clinical and radiological response to infliximab.
Methods:
We describe the case of a young female patient with biopsy-proven neurosarcoidosis leading to gait failure. She described significant corticosteroid-related side effects without clinical response to the therapy. Infliximab therapy was considered as a possible rescue medication.
Results:
Within months of starting intravenous infliximab therapy, she regained her ability to walk and magnetic resonance imaging identified significant improvements over a sustained course of infliximab therapy, including loss of enhancing nodules and loss of meningeal enhancement.
Conclusion:
Mounting evidence suggests that infliximab is a valuable pharmacological agent in the management of patients with refractory and disabling neurosarcoidosis. Controlled studies of infliximab in this condition are needed.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids